Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5267683 in an Adaptive, Randomized, Investigator-blind and Subject-blind, Multiple-ascending Dose, Placebo-controlled, Study Following Oral Administrations in Healthy Subjects for 28 Days
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs RO 5267683 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Roche
- 30 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 30 Jun 2012 Status is changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 May 2012 Planned end date changed from May 2012 to June 2012 as reported by ClinicalTrials.gov.